News & Press: General News

Industry Roundtable Seeks to Accelerate Clinical Research to Clinical Care

Wednesday, August 2, 2017   (0 Comments)
Posted by: Andres Bachelet
Share |

Academic researchers, government officials, industry to discuss critical new funding, collaborations and important research trends on September 25th in Washington, D.C.


Washington D.C, August 2, 2017- The Clinical Research Forum is pleased to announce that Dr. ShaAvhrée Buckman-Garner,  Director of the Office of Translational Sciences at the FDA, is the latest addition to a growing list of leading clinical research scientists and government leaders for the Industry Roundtable on September 25th in Washington, D.C.

She joinsDr. Larry Tabak, National Institutes of Health (NIH) Deputy Director, Dr. Joni Rutter, Director of Scientific Programs for the All of Us Research Program, and Dr. Joe Selby, Executive Director of the Patient-Centered Outcomes Research Institute (PCORI) for a panel presentation about the implementation of the 21st Century Cures Act. Congress passed the 21st Century Cures Act to accelerate the rate at which scientific breakthroughs are translated into treatments, therapies, and products that improve patient care. The panel will discuss progress on the 21st Century Cures initiatives and how these and related programs will further bolster clinical and translational research. 

“The Roundtable will explore some of the most pressing opportunities and challenges to enhance clinical research,” said Dr. Scott Steele, co-chair of the event and Director of Regulatory Science Programs at the University of Rochester.   “This is a rare opportunity to engage leaders from NIH, FDA, PCORI, industry and academia to discuss initiatives designed to advance translational research and medical product development.”

The Industry Roundtable will also feature a panel on the future challenges for industry-funded research, such as improving public/private partnerships and the increasing role of user fees in regulatory review. Confirmed speakers include Dr. Andrew Dahlem, Vice President and Chief Operating Officer of Lilly Research Laboratories, and Dr. Frank Weichold, Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) at the FDA.

“This year’s Industry Roundtable is forward-looking,” said Dr. Anantha Shekhar, co-chair of the event and a CR Forum board member, as well as Associate Vice President of Research for University Clinical Affairs at Indiana University. “We will be discussing the implementation of the important 21st Century Cures Act, and hear from leaders in the field about future collaborations and partnerships between government, industry and researchers to bring treatments to patients more rapidly.”

The Industry Roundtable is Monday, September 25, from 1pm to 5pm at the American College of Cardiology, 2400 N Street NW, Washington, D.C. 20037.